273 related articles for article (PubMed ID: 33710310)
1. BRCA1/2 and Endometrial Cancer Risk: Implications for Management.
Sherman ME; Foulkes WD
J Natl Cancer Inst; 2021 Sep; 113(9):1127-1128. PubMed ID: 33710310
[No Abstract] [Full Text] [Related]
2. RE: Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
Nahshon C; Lavie O
J Natl Cancer Inst; 2022 Feb; 114(2):320-321. PubMed ID: 34424329
[No Abstract] [Full Text] [Related]
3. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG
Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099
[TBL] [Abstract][Full Text] [Related]
4. Endometrial Cancer, BRCA1, and BRCA2 in the UK Biobank Cohort.
Lehrer S; Rheinstein PH
Am J Clin Oncol; 2021 Jul; 44(7):299-300. PubMed ID: 34008499
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic polymorphisms in AURKA, BRCA1, CCNE1 and CDK2 with the risk of endometrial carcinoma and clinicopathological parameters among Chinese Han women.
Zheng LY; Song AP; Chen L; Liu DG; Li XH; Guo HY; Tian XX; Fang WG
Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():65-72. PubMed ID: 25463638
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity of BRCA1, TP53 and TCRD markers analysed in sporadic endometrial cancer.
Niederacher D; An HX; Camrath S; Dominik SI; Göhring UJ; Oertel A; Grass M; Hantschmann P; Lordnejad MR; Beckmann MW
Eur J Cancer; 1998 Oct; 34(11):1770-6. PubMed ID: 9893667
[TBL] [Abstract][Full Text] [Related]
7. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families.
Duffy DL; Antill YC; Stewart CJ; Young JP; ; Spurdle AB
Twin Res Hum Genet; 2011 Apr; 14(2):111-8. PubMed ID: 21425892
[TBL] [Abstract][Full Text] [Related]
8. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
de Jonge MM; de Kroon CD; Jenner DJ; Oosting J; de Hullu JA; Mourits MJE; Gómez Garcia EB; Ausems MGEM; Margriet Collée J; van Engelen K; van de Beek I; ; Smit VTHBM; Rookus MA; de Bock GH; van Leeuwen FE; Bosse T; Dekkers OM; van Asperen CJ
J Natl Cancer Inst; 2021 Sep; 113(9):1203-1211. PubMed ID: 33710348
[TBL] [Abstract][Full Text] [Related]
9. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
Schrijver LH; Mooij TM; Pijpe A; Sonke GS; Mourits MJE; Andrieu N; Antoniou AC; Easton DF; Engel C; Goldgar D; John EM; Kast K; Milne RL; Olsson H; Phillips KA; Terry MB; Hopper JL; van Leeuwen FE; Rookus MA
J Natl Cancer Inst; 2022 Apr; 114(4):540-552. PubMed ID: 35048954
[TBL] [Abstract][Full Text] [Related]
10. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
11. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
[TBL] [Abstract][Full Text] [Related]
12. Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.
Lu G; Lu T; Pan J; Guo L; Pang Y; Liu P
Arch Gynecol Obstet; 2021 Jun; 303(6):1569-1579. PubMed ID: 33215232
[TBL] [Abstract][Full Text] [Related]
13. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications.
Casey MJ; Bewtra C; Lynch HT; Snyder CL; Stacey M
Int J Gynecol Cancer; 2015 May; 25(4):650-6. PubMed ID: 25756400
[TBL] [Abstract][Full Text] [Related]
14. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Reitsma W; Mourits MJ; de Bock GH; Hollema H
Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033
[TBL] [Abstract][Full Text] [Related]
15. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical loss of BRCA1 protein in uterine serous carcinoma.
Hecht JL; Konstantinopoulos PA; Awtrey CS; Soslow RA
Int J Gynecol Pathol; 2014 May; 33(3):282-7. PubMed ID: 24681740
[TBL] [Abstract][Full Text] [Related]
17. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
18. Studies on selected molecular factors in endometrial cancers.
Markowska A; Szarszewska M; Żurawski J; Sajdak S; Knapp P; Gryboś A; Olejek A; Bednarek W; Roszak A; Jóźwik M; Marszałek A; Filas V; Wójcik-Krowiranda K; Mądry R; Markowska J; Sozański R
Adv Clin Exp Med; 2018 Oct; 27(10):1417-1424. PubMed ID: 30277666
[TBL] [Abstract][Full Text] [Related]
19. Endometrial Cancer.
Lu KH; Broaddus RR
N Engl J Med; 2020 Nov; 383(21):2053-2064. PubMed ID: 33207095
[No Abstract] [Full Text] [Related]
20. A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain.
Koul A; Nilbert M; Borg A
Genes Chromosomes Cancer; 1999 Mar; 24(3):207-12. PubMed ID: 10451700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
